immunology-2018-scientifictracks

1 5

t h

I n t e r n a t i o n a l C o n f e r e n c e o n

Immunology

Journal of Clinical Immunology and Allergy

ISSN 2471-304X

J u l y 0 5 - 0 7 , 2 0 1 8

V i e n n a , A u s t r i a

Immunology 2018

Page 45

Zhou Xing, Insights Allergy Asthma Bronchitis 2018, Volume: 4

DOI: 10.21767/2471-304X-C1-002

ycobacterium tuberculosis

(Mtb) has evolved with robust mechanisms

to counter host defence mechanisms, and the world is still facing TB

epidemics despite decades of use of BCG vaccine and antibiotics. New TB

vaccines are needed. In spite of major progress made in developing TB vaccine

strategies with a dozen novel vaccines currently in the clinical pipeline, we

still do not have an effective TB vaccine. This raises the question whether

any major breakthroughs can be achieved without making a departure from

the current strategy which creates a state of near-natural immunity, imitating

the natural immunity developed after Mtb infection. Mounting new evidence

suggests that an effective new strategy ought to induce a state of all-around

unnatural immunity consisting of trained innate immunity, tissue resident

memory T cells, and anti-Mtb surface antibodies in the respiratory mucosa. We

will present the current state of knowledge and progress.

Biography

Zhou Xing was trained in Medicine and Anatomic Pathology

in China, and subsequently completed his PhD in Immunology

at McMaster University, Canada. Since 2007, he has been

Full Professor at McMaster Immunology Research Centre of

McMaster University. He is an author of up to 175 peer-reviewed

publications

Developing new TB vaccine strategies to take

aim at unnatural mucosal immunity

Zhou Xing

McMaster University, Canada